Systemic Mastocytosis – Pipeline Review, H2 2012

Systemic Mastocytosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Systemic Mastocytosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Mastocytosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis. Systemic Mastocytosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Systemic Mastocytosis.
- A review of the Systemic Mastocytosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Mastocytosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Systemic Mastocytosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Mastocytosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Systemic Mastocytosis 7
Systemic Mastocytosis Therapeutics under Development by Companies 9
Systemic Mastocytosis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Systemic Mastocytosis Therapeutics - Products under Development by Companies 14
Systemic Mastocytosis Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Systemic Mastocytosis Therapeutics Development 16
Novartis AG 16
Pharmacyclics, Inc. 17
AB Science 18
Systemic Mastocytosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
midostaurin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PCI-45261 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
masitinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PKC-412 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
thalidomide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
Pharmacyclics, Inc., H2 2012 17
AB Science, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35

List of Figures
Number of Products under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

• Three Tips to Choose the Best Business Web Hosting Service
  Most businesses are choosing web-based services for the convenience and additional features that they offer. Web hosting is a common internet service, which is preferred by the businesses to launch their businesses online. It is a simple process of renting a space on the server, which allows data storage. This space and data can be [...]
• Antimalarials- Common Malaria Drugs for Fast Recovery
  Malaria is one of the better-known types of the mosquito-borne infectious disease. This disease is caused by microorganisms known as protists, which are introduced into the human body thorough the bites of an infected female mosquito. Along with the common flu-like symptoms, malaria also causes several other health conditions such as gastroenteritis, septicemia and viral [...]
• How to Choose the Best Multicasting Router
  Communication is the basic of computer networking. Multicasting is a common communication process in computing, which takes place in the computing environment. Multicast is the delivery of information to a group of computers through single transmission. Digital copies of this transmission are automatically created in various other network elements. In simple terms, it is similar [...]
• Commonly Prescribed Drugs for Paget’s Disease
  Paget’s disease is a chronic health condition of the bones, which causes enlarged and misshapen bones. It is the second most common disease of bones after arthritis. This disease can cause expansion of the bones, which leads to bone pain, deformity, fractures and arthritis. Apart from bones, there is another type of this disease, which [...]
• Are There Any Safest Osteoporosis Drugs?
  Human bone structure ages along with the growing age. Bones from various parts of the body start losing strength and become weak and fragile through years of wear and tear. Appropriate care of the bones keeps them healthy for a longer period. Various diseases and health conditions can easily attack the bone structure. Conditions like [...]

• Travel and Tourism in Portugal to 2017

After declining in 2009 due to the global financial crisis, the rate of inbound tourism within the Portuguese travel and tourism sector improved. The country recorded an increase in the number of international visitors and tourist expenditure, primarily due to …

• Construction in Western Europe – Key Trends and Opportunities to 2017

Western Europe experienced a severe financial crisis during 2008 – 2009, with economic activity in the region contracting sharply. Reflecting ongoing weakness in the region, real GDP has yet to rise above the pre-2008 level, with ongoing debt problems in …

• The Insurance Industry in Turkmenistan, Key Trends and Opportunities to 2017

The Turkmen insurance industry is very small, both in terms of size and significance. Insurance penetration stood at just 0.2% in 2012, compared to the global average of 6.7%. Between 2008 and 2012 the industry achieved significant written premium value …

• Construction in Thailand – Key Trends and Opportunities to 2017

The Thai construction industry suffered a double blow between 2008 and 2012, firstly from the global economic crisis in 2008 -2009 and then from the record breaking floods in 2011, with activity levels declining by 5.3% in 2008 and 2.35 …

• Construction in Tunisia – Key Trends and Opportunities to 2017

Between 2008 and 2012 the Tunisian construction industry grew at a CAGR of 5.58% and valued TND8.9 billion (US$5.7 billion) in 2012. This was supported by private and public investments in infrastructural, residential, industrial and commercial construction projects. Despite some …

Pharmaceutical and healthcare market in Poland 2013

"......are markets. The experienced analysts at PMR have kept close watch on these changes, observing events and collecting data that documents variations in sales values of various medications, the value of the hospital market and best-selling medicines ac......"

Brazil Pharmaceuticals and Healthcare Report Q3 2013

"......or are substantial to foreign investors due to the country's positive long-term economic outlook, growing middle-class population and its traditional commitment to improve healthcare. Headline Expenditure Projections ? Pharmaceuticals: BRL52.4bn (US$......"

Global Database of the Top Pharmaceutical Preparation Producers – Company Names, Financial Performance, Key Executives, and Contact Details

"......00 pharmaceutical preparation producers in the world which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key market insights in a readily accessible and ......"

Global Database of the Top Biological Product Producers – Company Names, Financial Performance, Key Executives, and Contact Details

"......oduct producers in the world which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key market insights in a readily accessible and clearly presented format......"

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals

"......e report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2013. The report portrays detailed comparative ......"